Clinical Scorecard: Evaluating the Prognostic Role of ypN Status Following Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Unfavorable post-treatment nodal status associated with poorer overall survival (OS)
• Pooled hazard ratio for OS was 4.75 (95% CI 2.38 - 9.47)
• Disease-free survival (DFS) also negatively impacted by unfavorable ypN status
• Combined major pathological response (MPR)-ypN classification may further stratify prognosis
• Findings based on two retrospective studies; caution advised in interpretation

Guideline-Based Recommendations

Diagnosis

• Pathological assessment of nodal status post-neoadjuvant therapy is critical

Management

• Consider closer surveillance or treatment intensification for patients with unfavorable ypN status

Monitoring & Follow-up

• Monitor overall survival and disease-free survival outcomes in patients post-surgery

Risks

• Postoperative recurrence remains a significant risk despite neoadjuvant treatment

Patient & Prescribing Data

Patients with resectable NSCLC receiving neoadjuvant chemoimmunotherapy

Neoadjuvant chemoimmunotherapy improves pathological outcomes but not all patients benefit equally

Clinical Best Practices

• Utilize standardized pathological evaluations post-neoadjuvant therapy
• Incorporate both primary tumor response and nodal status in prognostic assessments
• Adhere to IASLC recommendations for pathological evaluation

Related Resources & Content

• Systematic Review Registration